Oculis strengthens its neuro-ophthalmology pipeline by acquiring Accure Therapeutics' lead asset Privosegtor, consolidating its position in a niche therapeutic area
Executive summary: Oculis Holding AG signed an asset purchase agreement with Accure Therapeutics to acquire Privosegtor, Accure's lead neuro-ophthalmology candidate, on August 10, 2026. The acquisition enhances Oculis' pipeline in a high-value, underserved therapeutic area, reducing reliance on internal R&D and accelerating potential market entry for a novel treatment.
Who is involved: Oculis Holding AG (Nasdaq: OCS), Accure Therapeutics S.L., and their respective leadership teams; the deal was announced via GlobeNewswire from Zug and Barcelona.
Likely next: Regulatory filings for the transfer of IP, potential initiation or continuation of preclinical/clinical development of Privosegtor under Oculis, and disclosure of financial terms in subsequent SEC filings.
Oculis Holding AG has entered into an asset purchase agreement with Accure Therapeutics to acquire Privosegtor, the latter's lead candidate for neuro-ophthalmological conditions. The transaction, announced on August 10, 2026, involves no disclosed financial terms but includes transfer of intellectual property and development rights. This move expands Oculis’ portfolio in a specialized therapeutic area with limited competition and high unmet medical need, potentially accelerating its path to commercialization in ophthalmic neurodegeneration. The deal reflects a broader trend of biopharma companies bolstering pipelines via targeted acquisitions rather than internal discovery alone.
Timeline
- — Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company (GlobeNewswire)
Analysis — what this means
Likely next events
- Oculis to file an 8-K with the SEC disclosing material terms of the asset purchase by August 17, 2026
- Pre-IND meeting with the FDA regarding Privosegtor development path expected Q4 2026
- Accure Therapeutics to update pipeline strategy following divestment of lead asset by September 2026
Sectors affected
- Neuro-ophthalmology therapeutics
- Biopharmaceutical M&A
- Ophthalmic drug development
Regulatory implications
- FDA oversight of IND transfer and potential bridging studies required for Privosegtor under new sponsor (Oculis)
- EU EMA may require validation of technology transfer documentation for ongoing clinical trials in Europe
- No immediate antitrust concerns given niche market and absence of overlapping commercial products
Historical parallels
- Novartis’ 2019 acquisition of Cadent Therapeutics’ ophthalmology pipeline for $310M upfront
- Roche’s 2020 purchase of Spark Therapeutics’ gene therapy assets in retinal degeneration
- Alcon’s 2021 acquisition of Ivantis’ miniaturized glaucoma device (Hydrus) to expand surgical portfolio